Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05518383CT.gov B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | — | Recruiting | — | — | — |
NCT01958996CT.gov Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Idarubicin (this asset) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Approved | B · 62 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | A |
| Melphalan | Ruijin Hospital | P4 | BBB |
| Axicabtagene Ciloleucel | Ruijin Hospital | P4 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Nivestim | Ruijin Hospital | P3 | BBB |
| Prednisone | Beth Israel Deaconess Medical Center | P4 | BBB |
| Adriamycin | Beth Israel Deaconess Medical Center | P4 | BBB |
| (+)-Vincristine | Beth Israel Deaconess Medical Center | P4 | BBB |
+42 more in the Diffuse Large B-Cell Lymphoma cohort
Other indications for Idarubicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | A · 81 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BBB · 76 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Idarubicin in Diffuse Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/idarubicin-diffuse-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →